Reports FY24 revenue $670,000 vs $740,000 last year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma initiates Phase 3 psoriasis study of piclidenoson
- CANF Earnings this Week: How Will it Perform?
- Can-Fite BioPharma Advances Canine Osteoarthritis Treatment with Vetbiolix Partnership
- Can-Fite BioPharma to Begin Phase II Study for Lowe Syndrome Treatment
- Can-Fite BioPharma to initiate Phase II study in Lowe Syndrome